Just Above the New Threshold: Triple Therapy After a History of Pneumonia
A patient who clears GOLD 2026's lowered eosinophil bar for escalating to triple therapy, with a real pneumonia history that makes the decision feel closer than the number alone suggests.
Harlan W. spent forty-one years welding hulls at the same shipyard, retired now nine years but still able to point out, from a moving car, exactly which ships in the harbor he personally worked on. His COPD has been on dual bronchodilator therapy — a long-acting beta-agonist and long-acting muscarinic antagonist together — for the past two years, and it held reasonably well until this year brought two moderate exacerbations, each requiring a burst of oral steroids and antibiotics but not hospitalization. The question in front of the team is whether to add an inhaled corticosteroid to his regimen, and it is complicated by something that would not have shown up on a chart review five years ago: a hospitalization for pneumonia two years back, fully resolved, but the kind of history that makes anyone reach for an inhaled steroid pause before adding one.
His blood eosinophil count, checked twice this year, has run 130/µL both times. Under GOLD’s 2026 update, that number sits meaningfully above the threshold for adding an inhaled corticosteroid to dual therapy in a patient who is exacerbating — the guideline sets that bar at 100 cells/µL, not a new figure in 2026 but a long-standing GOLD criterion many clinicians still misremember as higher, and reserves the non-steroid escalation options, azithromycin or roflumilast, specifically for patients who fall below it. Harlan is not borderline against the current number. He clears it by 30 cells with room on both sides of two separate measurements. What makes the decision feel closer than the arithmetic suggests is that the pneumonia-risk literature runs the opposite way from the reassurance his numbers might seem to offer. In the patient-level meta-analysis pooling ten GlaxoSmithKline COPD trials, pneumonia events were more frequent among patients with the lower eosinophil counts, not the higher ones, and GOLD 2026 names a history of recurrent pneumonia alongside a count under 100 as its two reasons to run an individualized benefit-risk assessment before adding a steroid. At 130 with a pneumonia admission behind him, Harlan is near both. Clearing the escalation threshold and clearing the pneumonia question are two different pieces of arithmetic, and only the first one is settled.
Deciding whether 130 is close enough to worry about
He clears GOLD 2026’s own escalation threshold with real margin — 130 against a bar of 100, confirmed on two separate measurements, not a single fluke draw. He has had two exacerbations this year on dual therapy alone. I would escalate to triple therapy now rather than continue a regimen that has already let two exacerbations through.
I want his pneumonia history on the table before we treat this as settled by the number alone. He was hospitalized for pneumonia two years ago, and inhaled corticosteroids carry a real, documented association with pneumonia risk in COPD. That is not a reason to refuse triple therapy outright, but it is a reason to slow down and name the risk to him directly rather than let a threshold comparison carry the whole decision.
The pneumonia concern is real, and I want to correct the direction we might instinctively assume it runs. The patient-level meta-analysis across ten GlaxoSmithKline COPD trials found pneumonia events more common in patients with the lower blood eosinophil counts, not the higher ones — so sitting at 130 rather than 400 is not the reassurance it sounds like, and GOLD 2026 lists recurrent pneumonia and a count under 100 side by side as its two triggers for an individualized benefit-risk assessment. None of that makes triple therapy wrong for him: two exacerbations on dual therapy is a present, documented harm, and 130 does clear the escalation bar. What it does mean is that the pneumonia plan is part of the prescription rather than boilerplate attached to it, and that his prior admission earns more weight in this decision, not less.
Agreed: escalate to inhaled triple therapy today, given his confirmed eosinophil count clearing GOLD 2026's revised threshold and his exacerbation history on dual therapy alone.
Agreed also: an explicit pneumonia-vigilance plan is documented in his chart specifically because of his prior hospitalization, distinct from and in addition to standard triple-therapy counseling — the hospitalist's concern was folded into the plan rather than left as an unresolved objection.